JP2001511431A - Ｉ型およびｉｉｉ型コラーゲン接着剤組成物 - Google Patents
Ｉ型およびｉｉｉ型コラーゲン接着剤組成物Info
- Publication number
- JP2001511431A JP2001511431A JP2000504171A JP2000504171A JP2001511431A JP 2001511431 A JP2001511431 A JP 2001511431A JP 2000504171 A JP2000504171 A JP 2000504171A JP 2000504171 A JP2000504171 A JP 2000504171A JP 2001511431 A JP2001511431 A JP 2001511431A
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- type
- composition
- adhesive
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 54
- 108010069502 Collagen Type III Proteins 0.000 title claims abstract description 53
- 102000001187 Collagen Type III Human genes 0.000 title claims abstract description 53
- 239000000853 adhesive Substances 0.000 title claims abstract description 47
- 102000008186 Collagen Human genes 0.000 claims abstract description 54
- 108010035532 Collagen Proteins 0.000 claims abstract description 54
- 229920001436 collagen Polymers 0.000 claims abstract description 54
- 239000000178 monomer Substances 0.000 claims abstract description 29
- 239000000565 sealant Substances 0.000 claims abstract description 26
- 108010041390 Collagen Type II Proteins 0.000 claims abstract description 18
- 102000000503 Collagen Type II Human genes 0.000 claims abstract description 18
- 239000003106 tissue adhesive Substances 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 13
- 102000012422 Collagen Type I Human genes 0.000 claims description 39
- 108010022452 Collagen Type I Proteins 0.000 claims description 39
- 210000001519 tissue Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 108010073385 Fibrin Proteins 0.000 claims description 13
- 102000009123 Fibrin Human genes 0.000 claims description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 13
- 229950003499 fibrin Drugs 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 108010049003 Fibrinogen Proteins 0.000 claims description 11
- 102000008946 Fibrinogen Human genes 0.000 claims description 11
- 229940012952 fibrinogen Drugs 0.000 claims description 11
- 108090000190 Thrombin Proteins 0.000 claims description 10
- 229960004072 thrombin Drugs 0.000 claims description 10
- 108010071289 Factor XIII Proteins 0.000 claims description 7
- 229940012444 factor xiii Drugs 0.000 claims description 7
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims description 7
- 230000000379 polymerizing effect Effects 0.000 claims description 6
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 5
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 18
- 230000029663 wound healing Effects 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 210000004872 soft tissue Anatomy 0.000 abstract description 6
- 239000013466 adhesive and sealant Substances 0.000 abstract description 4
- 229940075469 tissue adhesives Drugs 0.000 abstract description 4
- 238000007385 chemical modification Methods 0.000 abstract description 2
- 210000001367 artery Anatomy 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 238000007789 sealing Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 230000002439 hemostatic effect Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002583 angiography Methods 0.000 description 5
- 238000002399 angioplasty Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000010188 recombinant method Methods 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011546 protein dye Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000003685 thermal hair damage Effects 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 102100029203 F-box only protein 8 Human genes 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
- 101100334493 Homo sapiens FBXO8 gene Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 101100537375 Homo sapiens TMEM107 gene Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 239000004826 Synthetic adhesive Substances 0.000 description 1
- 102100036728 Transmembrane protein 107 Human genes 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 238000005219 brazing Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 238000013133 post surgical procedure Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 235000020302 vienna Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
- C09J189/04—Products derived from waste materials, e.g. horn, hoof or hair
- C09J189/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polymerisation Methods In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5387297P | 1997-07-28 | 1997-07-28 | |
| US60/053,872 | 1997-07-28 | ||
| PCT/US1998/015382 WO1999005180A1 (fr) | 1997-07-28 | 1998-07-28 | Compositions d'adhesif a base de collagene du type i et du type iii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001511431A true JP2001511431A (ja) | 2001-08-14 |
Family
ID=21987121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000504171A Withdrawn JP2001511431A (ja) | 1997-07-28 | 1998-07-28 | Ｉ型およびｉｉｉ型コラーゲン接着剤組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1000089A4 (fr) |
| JP (1) | JP2001511431A (fr) |
| CN (1) | CN1272118A (fr) |
| AU (1) | AU8662798A (fr) |
| CA (1) | CA2308146A1 (fr) |
| IL (1) | IL134249A0 (fr) |
| NO (1) | NO20000425L (fr) |
| WO (1) | WO1999005180A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505474A (ja) * | 2017-01-31 | 2020-02-20 | ジェニフィス，エルエルシー | 基質の調製のための方法及び組成物 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2339575A1 (fr) * | 1998-08-10 | 2000-02-24 | James W. Polarek | Compositions hemostatiques a base de collagene de type i et de type iii, a utiliser en tant que produit de scellement vasculaire et pansement |
| US6046160A (en) * | 1999-07-22 | 2000-04-04 | Deroyal Industries, Inc. | Composition and method for enhancing wound healing |
| WO2012048298A2 (fr) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Procédés et systèmes de culture et de récolte de cellules dans un système de bioréacteur à fibres creuses avec conditions de régulation |
| AU2013370223A1 (en) * | 2012-12-31 | 2015-08-06 | George David Falus | Lyophilized fibrin sealant for high volume hemorrhage |
| EP3068867B1 (fr) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Expansion de cellules dans un bioréacteur |
| WO2015148704A1 (fr) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Remplacement passif de milieu |
| CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
| WO2017004592A1 (fr) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Croissance cellulaire à l'aide de stimuli mécaniques |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| WO2018184028A2 (fr) | 2017-03-31 | 2018-10-04 | Terumo Bct, Inc. | Expansion cellulaire |
| CN109529098A (zh) * | 2018-12-03 | 2019-03-29 | 广州润虹医药科技股份有限公司 | 一种外科医用粘合剂 |
| JP2024511064A (ja) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | 細胞捕獲及び増殖 |
| CN116925240A (zh) * | 2023-08-09 | 2023-10-24 | 山东多美康生物医药有限公司 | 一种重组胶原蛋白及其表达方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
| FR2715309B1 (fr) * | 1994-01-24 | 1996-08-02 | Imedex | Composition adhésive, à usage chirurgical, à base de collagène modifié par coupure oxydative et non réticulé. |
| US5773577A (en) * | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
| US5634936A (en) * | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
-
1998
- 1998-07-28 IL IL13424998A patent/IL134249A0/xx unknown
- 1998-07-28 CN CN98808788A patent/CN1272118A/zh active Pending
- 1998-07-28 WO PCT/US1998/015382 patent/WO1999005180A1/fr not_active Application Discontinuation
- 1998-07-28 AU AU86627/98A patent/AU8662798A/en not_active Abandoned
- 1998-07-28 EP EP98938008A patent/EP1000089A4/fr not_active Withdrawn
- 1998-07-28 CA CA002308146A patent/CA2308146A1/fr not_active Abandoned
- 1998-07-28 JP JP2000504171A patent/JP2001511431A/ja not_active Withdrawn
-
2000
- 2000-01-27 NO NO20000425A patent/NO20000425L/no unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505474A (ja) * | 2017-01-31 | 2020-02-20 | ジェニフィス，エルエルシー | 基質の調製のための方法及び組成物 |
| JP7242553B2 (ja) | 2017-01-31 | 2023-03-20 | ジェニフィス，インコーポレイテッド | 基質の調製のための方法及び組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL134249A0 (en) | 2001-04-30 |
| EP1000089A1 (fr) | 2000-05-17 |
| WO1999005180A1 (fr) | 1999-02-04 |
| EP1000089A4 (fr) | 2001-08-29 |
| CN1272118A (zh) | 2000-11-01 |
| NO20000425D0 (no) | 2000-01-27 |
| CA2308146A1 (fr) | 1999-02-04 |
| AU8662798A (en) | 1999-02-16 |
| NO20000425L (no) | 2000-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030032143A1 (en) | Collagen type I and type III compositions for use as an adhesive and sealant | |
| US20020015724A1 (en) | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing | |
| JP3735677B2 (ja) | 酸化分解で変性させた非架橋コラーゲンをベースとする外科用接着性組成物 | |
| JP2002524110A (ja) | 血管密封材および創傷被覆材として用いるためのｉ型コラーゲンおよびｉｉｉ型コラーゲン止血性組成物 | |
| Jain et al. | Recent developments and clinical applications of surgical glues: An overview | |
| JP3483882B2 (ja) | アルデヒド−硬化されたタンパク質性接着剤 | |
| CA2087957C (fr) | Composition de fixation et de soudure tissulaire et sa methode d'utilisation | |
| US5510102A (en) | Plasma and polymer containing surgical hemostatic adhesives | |
| CA2696255C (fr) | Reticulation photoactivee d'une proteine ou d'un peptide | |
| US5464471A (en) | Fibrin monomer based tissue adhesive | |
| JP2001511431A (ja) | Ｉ型およびｉｉｉ型コラーゲン接着剤組成物 | |
| CN109200331B (zh) | 一种肺部封合医用凝胶及其制备方法与应用 | |
| US10441675B2 (en) | Joining and/or sealing tissues through photo-activated cross-linking of matrix proteins | |
| NZ330572A (en) | A nontoxic biodegradable biological adhesive based on macromolecular polyaldehyde and a collagen based component for surgical and therapeutic use | |
| JPH06508363A (ja) | 組織治療用組成物 | |
| JP2010504410A (ja) | 組織接着剤組成物およびその方法 | |
| Spotnitz et al. | Fibrin-based adhesives and hemostatic agents | |
| MXPA00001013A (en) | Collagen type i and type iii adhesive compositions | |
| Grimaldi et al. | Biotechnological Approaches to Hemostasis and Molecular Mechanisms of Wound Healing | |
| Lee et al. | Biologic adhesives and hemostatic agents | |
| LeMaire et al. | 24 Surgical adhesives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20051004 |